CoChat

Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study

Open access

The DOI matches its Crossref record; 58 of the 64 references it cites were found in a registry or an index; 38 of the 73 sources its claims cite were checked for support.

Abstract

Several studies of the effects on cognition of selective serotonin reuptake inhibitors (SSRI), administered either acutely or sub-chronically in healthy volunteers, have found changes in learning and reinforcement outcomes. In contrast, to our knowledge, there have been no studies of chronic effects of escitalopram on cognition in healthy volunteers. This is important in view of its clinical use in major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). Consequently, we aimed to investigate the chronic effect of the SSRI, escitalopram, on measures of 'cold' cognition (including inhibition, cognitive flexibility, memory) and 'hot cognition' including decision-making and particularly reinforcement learning. The study, conducted at the University of Copenhagen between May 2020 and October 2021, used a double-blind placebo-controlled design with 66 healthy volunteers, semi-randomised to receive either 20 mg of escitalopram (n = 32) or placebo (n = 34), balanced for age, sex and intelligence quotient (IQ) for at least 21 days. Questionnaires, neuropsychological tests and serum escitalopram measures were taken. We analysed group differences on the cognitive measures using linear regression models as well as innovative hierarchical Bayesian modelling of the Probabilistic Reversal Learning (PRL) task. The novel and important finding was that escitalopram reduced reinforcement sensitivity compared to placebo on both the Sequential Model-Based/Model-Free task and the PRL task. We found no other significant group differences on 'cold' or 'hot' cognition. These findings demonstrate that serotonin reuptake inhibition is involved in reinforcement learning in healthy individuals. Lower reinforcement sensitivity in response to chronic SSRI administration may reflect the 'blunting' effect often reported by patients with MDD treated with SSRIs. Trial Registration: NCT04239339 .

Overview

CoChat Summary

TL;DR

In healthy volunteers, chronic escitalopram (20 mg daily for at least 21 days) reduced reinforcement sensitivity on two independent reinforcement-learning tasks compared with placebo, without affecting other ‘cold’ or ‘hot’ cognitive measures. The authors suggest this may relate to the clinical ‘blunting’ effect reported by patients on chronic SSRIs.

Key findings

  • Escitalopram reduced reinforcement sensitivity in hierarchical Bayesian modelling of the Probabilistic Reversal Learning task: mean difference = −2.77 [90% HDI, −5.29 to −0.40].
  • Escitalopram also reduced reinforcement sensitivity on the Sequential Model-Based/Model-Free task: Reward × Group interaction estimated coefficient = −0.34, p < 0.01, 95% CI [−0.57 to −0.11].
  • There were no significant group differences for reward learning rate, punishment learning rate, or stimulus stickiness in the PRL model, and no significant group differences on any ‘hot’ or ‘cold’ cognitive outcomes that survived multiple comparisons.
  • The escitalopram group had significantly higher dysfunction on CSFQ-14 orgasm/ejaculation dimension 5 and phase 3: t(42.25) = 2.68, p = 0.01, Cohen’s d = 0.68; there was no sex difference for the change score.

Methods

  • Double-blind, placebo-controlled, semi-randomised study with 66 healthy volunteers: 32 received escitalopram 20 mg daily and 34 received placebo for at least 21 days (escitalopram mean(s.d.) = 26.06(2.78) days; placebo = 26.09(3.29) days); participants were matched for age, sex, and IQ.
  • Participants completed questionnaires and an extensive neuropsychological battery assessing ‘cold’ and ‘hot’ cognition, including Probabilistic Reversal Learning, Sequential Model-Based/Model-Free, stop-signal/go-no-go, set-shifting, memory, attention, decision-making, social cognition, and emotion tasks; serum escitalopram was measured by UPLC-MS/MS.
  • Group comparisons used linear regression models with age, sex, IQ, and baseline reaction time as covariates, with Benjamini-Hochberg FDR q = 0.05; PRL data were analysed with hierarchical Bayesian reinforcement-learning models, and MBMF data with generalised linear mixed-effects regression.

Limitations

  • The paper states there was a significant difference in guessing group allocation: 53% of the escitalopram group correctly guessed escitalopram, whereas 15.6% of the placebo group guessed escitalopram (χ2(1, N = 65) = 10.46, p = 0.01); the authors note the escitalopram group was at chance level and argue results are unlikely affected given the lack of cognitive changes and specificity of the effect.
  • The authors state they cannot rule out that neuroplasticity effects might be greater with a longer duration of escitalopram, and that there is no reliable non-invasive way to determine interstitial serotonin concentrations in humans, making interpretation inferential.
  • The authors note the sample was cognitively high-performing (average IQ > 110) healthy volunteers, so effects may differ from patients with MDD; they also report that exact sample sizes varied slightly across tasks due to technical issues and time constraints.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41386-022-01523-x

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Computational modelling results from the Probabilistic Reversal Learning (PRL) Task. Error bars in orange indicate credible differences in posterior distributions between placebo and escitalopram groups for which the 90% highest density interval (HDI) excluded 0.
Fig. 1 Computational modelling results from the Probabilistic Reversal Learning (PRL) Task. Error bars in orange indicate credible differences in posterior distributions between placebo and escitalopram groups for which the 90% highest density interval (HDI) excluded 0.CC BY · PubMed Central
Fig. 2 Proportion of ‘stay’ choices of the Sequential Model-Based/Model Free Task. A The proportion of first-stage stay choices is shown as a function of outcome of the previous trial for each group, separately for trials following common and rare transitions. The figure shows that both the placebo and escitalopram groups responded in a model-based way. B The proportion of first-stage stay choices is graphed as a function of outcome of the previous trial for each group averaged across transition type. The figure shows that the escitalopram group were less likely to stay following a reward compared to the placebo group. This result suggests lower reinforcement sensitivity in the escitalopram group. The error bars represent ±1 SEM.
Fig. 2 Proportion of ‘stay’ choices of the Sequential Model-Based/Model Free Task. A The proportion of first-stage stay choices is shown as a function of outcome of the previous trial for each group, separately for trials following common and rare transitions. The figure shows that both the placebo and escitalopram groups responded in a model-based way. B The proportion of first-stage stay choices is graphed as a function of outcome of the previous trial for each group averaged across transition type. The figure shows that the escitalopram group were less likely to stay following a reward compared to the placebo group. This result suggests lower reinforcement sensitivity in the escitalopram group. The error bars represent ±1 SEM.CC BY · PubMed Central

Verification

Claims the paper makes

27 Valid · 1 Not valid · 12 Not checked · 32 Own results and interpretations

17 more claims

Create a free account to see all 72 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 38
  • It may state two separate claims as one. 25

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • Consistentt(63) = 0.04reported p = .97 · recomputed p = .968

    “t(63) = 0.04, p = .97”

  • Consistentχ²(1) = 10.46reported p = .01 · recomputed p = .001

    “χ2 (1, N = 65) = 10.46, p = .01”

    The paper prints p at a floor (such as p < .001)

  • Consistentt(42.25) = 2.68reported p = .01 · recomputed p = .010

    “t (42.25) = 2.68, p = .01”

  • Consistentt(42.25) = 2.68reported p = .01 · recomputed p = .010

    “t(42.25) = 2.68, p = .01”

  • Consistentt(64) = -1.15reported p = .25 · recomputed p = .254

    “t(64) = −1.15, p = .25”

5 of 5

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Citations

Cites

Show all 58 references

Cited by

See all 61

Metadata

Authors
Langley, C., Armand, S., Luo, Q., Savulich, G., Segerberg, T., Søndergaard, A., Pedersen, E. B., Svart, N., Overgaard-Hansen, O., Johansen, A., Borgsted, C., Cardinal, R. N., Robbins, T. W., Stenbæk, D. S., Knudsen, G. M., & Sahakian, B. J.
Affiliations
  • University of Cambridge (GB)
  • University of Copenhagen (DK)
  • Fudan University (CN)
Corresponding author
Langley, Christelle
Venue
Neuropsychopharmacology
Published
2023-01-23
Volume
48
Issue
4
Pages
664-670
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W4317715429
Cited by
58
References
64
Citations by year
2026: 16 · 2025: 19 · 2024: 16 · 2023: 7
FWCI
7.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
  • Apollo
Funders
Lundbeckfonden
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
escitalopram, selective serotonin reuptake inhibitors, long-term drug effects, reinforcement learning, reinforcement sensitivity, probabilistic reversal learning, decision-making, cognitive flexibility, inhibition, memory, serotonin reuptake inhibition, major depressive disorder, obsessive-compulsive disorder
MeSH terms
Escitalopram, Bayes Theorem, Major Depressive Disorder, Double-Blind Method, Humans, Infant, Newborn, Citalopram, Selective Serotonin Reuptake Inhibitors, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. https://app.cochat.ai/papers/10.1038/s41386-022-01523-x
The paper
Langley, C., Armand, S., Luo, Q., Savulich, G., Segerberg, T., Søndergaard, A., Pedersen, E. B., Svart, N., Overgaard-Hansen, O., Johansen, A., Borgsted, C., Cardinal, R. N., Robbins, T. W., Stenbæk, D. S., Knudsen, G. M., & Sahakian, B. J. (2023). Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01523-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.